Mansour Salesi1,2, Behrokh Shojaie3,4, Ziba Farajzadegan5, Naghmeh Salesi6, Erfan Mohammadi6. 1. Division of Rheumatology, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. salesi@med.mui.ac.ir. 2. Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. salesi@med.mui.ac.ir. 3. Division of Rheumatology, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 4. Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. 5. Department of Community and Family Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 6. Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, Iran.
Abstract
INTRODUCTION: The interaction between angiotensin-converting enzyme 2 (ACE2) and SARS-CoV-2 is a crucial factor in the viral infections leading to the release of inflammatory proteins, such as TNF-α. Thus, it is hypothesized that TNF-α blockers can prevent either COVID-19 incidence or its serious symptoms. TNF-α blockers are prescribed to treat various autoimmune disorders, including rheumatoid arthritis (RA) and seronegative spondyloarthropathies (SpA). Therefore, the objective of this work was to examine this hypothesis that TNF-α blockers can prevent COVID-19 incidence in patients with RA or SpA. METHODS: A case-control study was conducted through interviews based on a structured questionnaire to investigate the frequency of COVID-19 incidence in 254 eligible patients with RA or SpA about whom 45% were under treatment with one type of TNF-α blockers including infliximab, adalimumab, and etanercept at least for 3 months during the COVID-19 pandemic. Interviews were carried out twice, at the beginning and the end of the study (June-December 2020). Patients with COVID-19 during the study or before that were considered as cases. The control group was patients without COVID-19 experience. Data were analyzed using descriptive statistics, and logistic regression was used to determine the relationships between COVID-19 incidence and independent variables. RESULTS: A small percentage of patients treated with TNF-α blockers (5.22%, 6/115) experienced COVID-19, while a large percentage of patients with COVID-19 did not receive TNF-α blockers (27.34%, 38/139). According to odds ratio, adalimumab, infliximab, and etanercept decreased significantly the risk of developing COVID-19 up to 96.8, 95, and 80.3% (p < 0.05), respectively. Therefore, TNF-α blockers could probably decrease the chances of the COVID-19 incidence in patients with RA or SpA. CONCLUSIONS: A direct and positive correlation between the use of TNF-α blockers and a reduction in the incidence of COVID-19 could suggest the prophylactic role of these drugs in preventing COVID-19 in patients with RA and SpA.
INTRODUCTION: The interaction between angiotensin-converting enzyme 2 (ACE2) and SARS-CoV-2 is a crucial factor in the viral infections leading to the release of inflammatory proteins, such as TNF-α. Thus, it is hypothesized that TNF-α blockers can prevent either COVID-19 incidence or its serious symptoms. TNF-α blockers are prescribed to treat various autoimmune disorders, including rheumatoid arthritis (RA) and seronegative spondyloarthropathies (SpA). Therefore, the objective of this work was to examine this hypothesis that TNF-α blockers can prevent COVID-19 incidence in patients with RA or SpA. METHODS: A case-control study was conducted through interviews based on a structured questionnaire to investigate the frequency of COVID-19 incidence in 254 eligible patients with RA or SpA about whom 45% were under treatment with one type of TNF-α blockers including infliximab, adalimumab, and etanercept at least for 3 months during the COVID-19 pandemic. Interviews were carried out twice, at the beginning and the end of the study (June-December 2020). Patients with COVID-19 during the study or before that were considered as cases. The control group was patients without COVID-19 experience. Data were analyzed using descriptive statistics, and logistic regression was used to determine the relationships between COVID-19 incidence and independent variables. RESULTS: A small percentage of patients treated with TNF-α blockers (5.22%, 6/115) experienced COVID-19, while a large percentage of patients with COVID-19 did not receive TNF-α blockers (27.34%, 38/139). According to odds ratio, adalimumab, infliximab, and etanercept decreased significantly the risk of developing COVID-19 up to 96.8, 95, and 80.3% (p < 0.05), respectively. Therefore, TNF-α blockers could probably decrease the chances of the COVID-19 incidence in patients with RA or SpA. CONCLUSIONS: A direct and positive correlation between the use of TNF-α blockers and a reduction in the incidence of COVID-19 could suggest the prophylactic role of these drugs in preventing COVID-19 in patients with RA and SpA.
Authors: Johannes P D Schultheiss; Eelco C Brand; Evert Lamers; Willemijn C M van den Berg; Fiona D M van Schaik; Bas Oldenburg; Herma H Fidder Journal: Aliment Pharmacol Ther Date: 2019-07-16 Impact factor: 8.171
Authors: David Simon; Koray Tascilar; Gerhard Krönke; Arnd Kleyer; Mario M Zaiss; Franz Heppt; Christine Meder; Raja Atreya; Entcho Klenske; Peter Dietrich; Abdullah Abdullah; Thorsten Kliem; Giulia Corte; Harriet Morf; Moritz Leppkes; Andreas E Kremer; Andreas Ramming; Milena Pachowsky; Florian Schuch; Monika Ronneberger; Stefan Kleinert; Clara Maier; Axel J Hueber; Karin Manger; Bernhard Manger; Carola Berking; Matthias Tenbusch; Klaus Überla; Michael Sticherling; Markus F Neurath; Georg Schett Journal: Nat Commun Date: 2020-07-24 Impact factor: 14.919
Authors: Rebecca Haberman; Jordan Axelrad; Alan Chen; Rochelle Castillo; Di Yan; Peter Izmirly; Andrea Neimann; Samrachana Adhikari; David Hudesman; Jose U Scher Journal: N Engl J Med Date: 2020-04-29 Impact factor: 91.245